These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 20500805

  • 1. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP, Koch MW, Steen C, Heersema DJ, De Groot JC, De Keyser J.
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [Abstract] [Full Text] [Related]

  • 2. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
    Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol Dl, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F.
    Mult Scler; 2009 May; 15(5):632-7. PubMed ID: 19389751
    [Abstract] [Full Text] [Related]

  • 3. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
    Enzinger C, Fuchs S, Pichler A, Wallner-Blazek M, Khalil M, Langkammer C, Ropele S, Fazekas F.
    Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
    [Abstract] [Full Text] [Related]

  • 4. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis.
    Dalton CM, Bodini B, Samson RS, Battaglini M, Fisniku LK, Thompson AJ, Ciccarelli O, Miller DH, Chard DT.
    Mult Scler; 2012 Mar; 18(3):322-8. PubMed ID: 21878451
    [Abstract] [Full Text] [Related]

  • 5. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, Yaung K, Helenowski IB, Jovanovic B, Spahovic D, Arnautovic I, Lee DC, Benefield BC, Futterer S, Oliveira MC, Burman J.
    JAMA; 2015 Jan 20; 313(3):275-84. PubMed ID: 25602998
    [Abstract] [Full Text] [Related]

  • 6. Cervical cord lesion load is associated with disability independently from atrophy in MS.
    Kearney H, Altmann DR, Samson RS, Yiannakas MC, Wheeler-Kingshott CA, Ciccarelli O, Miller DH.
    Neurology; 2015 Jan 27; 84(4):367-73. PubMed ID: 25540312
    [Abstract] [Full Text] [Related]

  • 7. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
    Ge Y, Grossman RI, Udupa JK, Wei L, Mannon LJ, Polansky M, Kolson DL.
    Radiology; 2000 Mar 27; 214(3):665-70. PubMed ID: 10715027
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D.
    Mult Scler; 2012 Aug 27; 18(8):1092-8. PubMed ID: 22695538
    [Abstract] [Full Text] [Related]

  • 13. Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis.
    Mostert JP, de Groot JC, Ramsaransing GS, Koch MW, De Keyser J.
    Eur J Neurol; 2007 Nov 27; 14(11):1210-5. PubMed ID: 17956444
    [Abstract] [Full Text] [Related]

  • 14. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S, Neema M, Healy BC, Weiner HL, Bakshi R.
    J Neurol Sci; 2014 Nov 15; 346(1-2):250-4. PubMed ID: 25220114
    [Abstract] [Full Text] [Related]

  • 15. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R, MN166-001 Investigators.
    Neurology; 2010 Mar 30; 74(13):1033-40. PubMed ID: 20200338
    [Abstract] [Full Text] [Related]

  • 16. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?
    Strasser-Fuchs S, Enzinger C, Ropele S, Wallner M, Fazekas F.
    Mult Scler; 2008 Mar 30; 14(2):205-11. PubMed ID: 17986507
    [Abstract] [Full Text] [Related]

  • 17. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F, Absinta M, Sormani MP, Ghezzi A, Bertolotto A, Montanari E, Comi G, Filippi M.
    Brain; 2007 Aug 30; 130(Pt 8):2211-9. PubMed ID: 17535835
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C, Battaglini M, Stromillo ML, Bartolozzi ML, Guidi L, Federico A, De Stefano N.
    Arch Neurol; 2008 Feb 30; 65(2):236-43. PubMed ID: 18268194
    [Abstract] [Full Text] [Related]

  • 20. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
    van Walderveen MA, Lycklama A Nijeholt GJ, Adèr HJ, Jongen PJ, Polman CH, Castelijns JA, Barkhof F.
    Arch Neurol; 2001 Jan 30; 58(1):76-81. PubMed ID: 11176939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.